We are live on ! Find out more
OGEN icon

Oragenics
OGEN

10 hedge funds and large institutions have $182K invested in Oragenics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,921% more capital inflows, than outflows

Capital inflows: $30.7K | Capital outflows: $1.02K

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0% more funds holding

Funds holding: 10 → 10 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.17% less ownership

Funds ownership: 2.59% → 2.42% (-0.17%)

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$24.5K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$3.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.7K
4
Osaic Holdings
Osaic Holdings
Arizona
+$100

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$899
2
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
-$116

OGEN Hedge Fund Activity: Q3 2023 in Review

10 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q3 2023, worth a combined $182K — up 5% from $174K a quarter earlier.

Fund positioning in OGEN was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $24.5K. The largest seller was UBS Group, cutting an estimated $899.

  • 10 institutional investors held Oragenics (OGEN) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $182K of Oragenics stock for Q3 2023, up 5% quarter-over-quarter.
  • 1 fund opened new Oragenics positions in Q3 2023 and 1 closed out, a net change of 0 holders.
  • The largest Oragenics buyer in Q3 2023 was Geode Capital Management, an estimated $24.5K added.
  • The largest Oragenics seller in Q3 2023 was UBS Group, an estimated $899 sold.

Based on aggregated 13F filings for Q3 2023.